0001415889-17-000640.txt : 20170414
0001415889-17-000640.hdr.sgml : 20170414
20170414172254
ACCESSION NUMBER: 0001415889-17-000640
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170412
FILED AS OF DATE: 20170414
DATE AS OF CHANGE: 20170414
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MABVAX THERAPEUTICS HOLDINGS, INC.
CENTRAL INDEX KEY: 0001109196
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930987903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11535 SORRENTO VALLEY ROAD
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8582599405
MAIL ADDRESS:
STREET 1: 11535 SORRENTO VALLEY ROAD
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: TELIK INC
DATE OF NAME CHANGE: 20000313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HANSON GREGORY P
CENTRAL INDEX KEY: 0001186120
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37861
FILM NUMBER: 17763285
MAIL ADDRESS:
STREET 1: MABVAX THERAPEUTICS HOLDINGS, INC.
STREET 2: 11588 SORRENTO VALLEY ROAD SUITE 20
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
form4-04142017_020445.xml
X0306
4
2017-04-12
0001109196
MABVAX THERAPEUTICS HOLDINGS, INC.
MBVX
0001186120
HANSON GREGORY P
C/O MABVAX THERAPEUTICS HOLDINGS, INC.
11535 SORRENTO VALLEY RD., SUITE 400
SAN DIEGO
CA
92121
false
true
false
false
CHIEF FINANCIAL OFFICER, SECR
Common Stock
2017-04-12
4
S
0
3885
2.0001
D
29206
D
Represents the remaining portion of the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II of the reporting person's Form 4, as filed with the Securities and Exchange Commission on April 4, 2017. This sale is mandated by the Issuer's election under the equity incentive plan to require satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $2.0162 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jeremy D. Glaser , Attorney-in-Fact
2017-04-14